STOCKHOLM, Sweden--(BUSINESS WIRE)--Regulatory News: Medivir is developing selective cathepsin K inhibitors for the treatment of osteoporosis and osteoarthritis. Medivir has now designated a highly active and selective small molecule inhibitor of cathepsin K, MIV-710, as Candidate Drug (CD).
